Key result
Applying revised cutoff values for [I]/IC50 < 0.1 and [I2]/IC50 < 5 reduced the false negative rate for predicting clinically relevant digoxin drug interactions from 36% to 9%.
Why the study?
Do revised cutoff values for [I]/IC50 and [I2]/IC50 improve the prediction of clinically relevant P-glycoprotein related digoxin drug interactions?
Do revised cutoff values for [I]/IC50 and [I2]/IC50 improve the prediction of clinically relevant P-glycoprotein related digoxin drug interactions?
Absolute Event Rate: 9% vs 36%
Revised in vitro cutoff values for P-glycoprotein inhibition significantly reduce false negative predictions for clinical digoxin drug interactions.
No takes yet. Share an insight, caveat, or question.
May refine in vitro P-gp DDI screening for digoxin; leaves open clinical validation before practice impact.
Cook et al. (2009) studied Clinical digoxin drug interactions (DDIs). Revised cutoff values for [I]/IC50 < 0.1 and [I2]/IC50 < 5 vs. Individual ratios was evaluated on False negative rate for predicting clinically relevant digoxin drug interactions. Applying revised cutoff values for [I]/IC50 < 0.1 and [I2]/IC50 < 5 reduced the false negative rate for predicting clinically relevant digoxin drug interactions from 36% to 9%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: